NASDAQ · EVFM
Healthcare · Biotechnology
$0.01
Up+$0.00 (+0.00%)
Updated Oct 12, 2026, 11:54 AM
SID Score
4.0/10
Composite research score
Smart Money
—
Institutional and insider signal
Price performance · EVFM
1M range · 0 trading sessions · Daily adjusted prices
EVFM does not have enough price history for the selected period.
Data unavailable
Market data is busy. Please try again shortly.
The latest Smart Investors Daily articles mentioning EVFM.
Company
Market Activity
Research & News
EVFM research
Company profile and research snapshot.
EVOFEM BIOSCIENCE INC
Visit company websiteConsensus and target data currently published for this company.
| Date | Firm | Rating | Target |
|---|---|---|---|
| Dec 13, 2023 | Laidlaw & Co. | Hold | — |
| Oct 13, 2022 | Stifel | Hold | — |
| Aug 15, 2022 | HC Wainwright & Co. | Buy | — |
| Jul 15, 2022 | Morgan Stanley | Underweight | — |
| Jun 2, 2022 | Laidlaw & Co. | Buy | — |
No generated briefing is available yet.
Benzinga · Nov 21, 2025
Evofem Biosciences received favorable pricing certificates from Emirates Drug Establishment for PHEXX, a hormone-free contraceptive vaginal gel, marking a key step towards commercialization in the UAE in 2026.
Benzinga · Nov 13, 2025
Women's health company Evofem Biosciences reported increased net sales of $5.0 million in Q3 2025, a 10% increase from the previous year. The company achieved $1.0 million in operating income, reduced operating expenses by 42%, and advanced strategies to lower manufacturing costs for its products PHEXX and SOLOSEC.
defenseworld.net · Nov 2, 2025
Profitability This table compares Evofem Biosciences and Calliditas Therapeutics AB (publ)'s net margins, return on equity and return on assets. Net Margins Return on Equity Return on Assets Evofem Biosciences -46.42% -91.97% -61.93% Calliditas Therapeutics AB (publ) -30.18% -212.04% -27.96% Valuation and Earnings This table compares Evofem Biosciences and Calliditas Therapeutics AB (publ)"s gross revenue,
Interpretive context generated from the platform’s current data sources.
No results
AI research layers have not been published yet.
The latest Smart Investors Daily articles mentioning EVFM.
